CCM
GILD icon

Crossvault Capital Management’s Gilead Sciences GILD Stock Holding History

Crossvault Capital Management’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		$1.25M Sell
20,295
-1,600
-7% -$99.1K 0.49% 39
2022
Q1 		$1.3M Sell
21,895
-3,630
-14% -$232K 0.42% 42
2021
Q4 		$1.85M Buy
25,525
+3,200
+14% +$220K 0.56% 41
2021
Q3 		$1.56M Buy
22,325
+400
+2% +$28.1K 0.49% 40
2021
Q2 		$1.5M Sell
21,925
-1,576
-7% -$105K 0.46% 42
2021
Q1 		$1.52M Sell
23,501
-900
-4% -$58K 0.54% 40
2020
Q4 		$1.42M Sell
24,401
-2,925
-11% -$176K 0.53% 40
2020
Q3 		$1.73M Buy
27,326
+270
+1% +$18.7K 0.75% 35
2020
Q2 		$2.08M Buy
27,056
+276
+1% +$21.2K 0.96% 29
2020
Q1 		$2M Sell
26,780
-4,526
-14% -$313K 1.12% 28
2019
Q4 		$2.03M Sell
31,306
-9,200
-23% -$599K 0.89% 31
2019
Q3 		$2.57M Buy
40,506
+2,655
+7% +$174K 1.22% 27
2019
Q2 		$2.56M Sell
37,851
-593
-2% -$39K 1.25% 26
2019
Q1 		$2.5M Sell
38,444
-2,300
-6% -$153K 1.29% 25
2018
Q4 		$2.55M Sell
40,744
-7,278
-15% -$509K 1.45% 24
2018
Q3 		$3.71M Sell
48,022
-2,103
-4% -$159K 1.91% 20
2018
Q2 		$3.55M Sell
50,125
-75
-0.1% -$5.3K 1.89% 21
2018
Q1 		$3.79M Sell
50,200
-725
-1% -$57.6K 2.15% 19
2017
Q4 		$3.65M Sell
50,925
-21,625
-30% -$1.64M 1.92% 22
2017
Q3 		$5.88M Buy
72,550
+6,450
+10% +$493K 3.37% 10
2017
Q2 		$4.68M Buy
66,100
+13,374
+25% +$890K 2.81% 17
2017
Q1 		$3.58M Buy
52,726
+2,100
+4% +$148K 2.22% 22
2016
Q4 		$3.63M Sell
50,626
-1,565
-3% -$116K 2.45% 20
2016
Q3 		$4.13M Buy
52,191
+2,320
+5% +$188K 2.88% 15
2016
Q2 		$4.16M Buy
49,871
+4,345
+10% +$386K 2.94% 14
2016
Q1 		$4.18M Buy
45,526
+240
+0.5% +$21.6K 3.08% 14
2015
Q4 		$4.58M Buy
45,286
+5,401
+14% +$562K 3.26% 9
2015
Q3 		$3.92M Buy
39,885
+6,335
+19% +$704K 3.06% 14
2015
Q2 		$3.93M Buy
33,550
+13,510
+67% +$1.48M 3.14% 13
2015
Q1 		$1.97M Buy
20,040
+6,165
+44% +$626K 1.57% 27
2014
Q4 		$1.31M Buy
+13,875
New +$1.44M 1.14% 32

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Crossvault Capital Management's GILD Position: Q2 2022 in Review

Crossvault Capital Management reduced its Gilead Sciences (GILD) stake by 7.3% in Q2 2022, selling an estimated $99.1K and leaving 20,295 shares worth $1.25M. The position accounts for 0.49% of the portfolio, ranked #39.

Crossvault Capital Management first reported a position in GILD in Q4 2014 and has held it in 31 quarters since. The position peaked at $5.88M in Q3 2017. 1,603 funds tracked by Wall St. Rank hold GILD as of Q2 2022.

  • Crossvault Capital Management held 20,295 shares of Gilead Sciences worth $1.25M as of Q2 2022.
  • Crossvault Capital Management sold 1,600 Gilead Sciences shares in Q2 2022, an estimated $99.1K.
  • Gilead Sciences made up 0.49% of Crossvault Capital Management's portfolio in Q2 2022, its #39 holding.
  • Crossvault Capital Management first reported a position in Gilead Sciences in Q4 2014 and has held it in 31 quarters since.
  • Crossvault Capital Management's Gilead Sciences position peaked at $5.88M in Q3 2017.
  • 1,603 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2022.

Based on Crossvault Capital Management's 13F filing for Q2 2022, filed 8 Aug 2022.